Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CBP-201 · 3 trials · 2 indications
The percentage of subjects whose IGA score is 0-1 and decreased by ≥2 points The Validated Investigator Global Assessment for AD (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Absolute change from Baseline in prebronchodilator (trough) FEV1 at Week 12. To assess the efficacy of CBP-201 (Dose 1 and Dose 2) versus placebo in patients with moderate to severe persistent asthma with type 2 inflammation as measured by lung function improvements.
EASI=Eczema Area Severity Index is a validated physician score for signs of atopic dermatitis. EASI can range from 0 to 72. An EASI score of 0 indicates clear/no eczema, 0.1 to 1.0 almost clear, 1.1 to 7 mild disease, 7.1 to 21 moderate disease, 21.1 to 50 severe disease, and 51-72 indicates very severe disease. EASI Sub-scale ranges are as follows: Head/neck can range from 0-7.2, Trunk 0-14.4, Upper Extremities 0-21.6, Lower Extremities can range from 0-28.8. To calculate EASI, % involvement is first assessed by body region with an Area involvement Score of 0-6 for each region: 0=0%, 1=1-9%, 2=10-29%, 3=30-39%, 4=50-69%, 5=70-89%, 6=90-100% involvement. Then 4 attributes (Erythema, Edema/Papulation, Excoriation, and Lichenification) are scored for severity (0= none, 1=mild, 2=moderate, 3=severe). A multiplier is applied head/neck=0.1, trunk=0.2, upper extremities= 0.3, lower extremities=0.4. The total EASI score is the sum of 4 regional sub-scores.
| Arm | Type | Description |
|---|---|---|
| CBP-201 Dose | EXPERIMENTAL | CBP-201 Dose subcutaneous (SC) injection |
| Placebo | PLACEBO_COMPARATOR | subcutaneous (SC) injection |
| CBP-201 Dose 1 | EXPERIMENTAL | CBP-201 Dose 1 subcutaneous (SC) injection. |
| CBP-201 Dose 2 | EXPERIMENTAL | CBP-201 Dose 2 subcutaneous (SC) injection. |
| CBP-201 Dose 3 | EXPERIMENTAL | CBP-201 Dose 3 subcutaneous (SC) injection |
| Name | Type | Description |
|---|---|---|
| CBP-201 | DRUG | CBP-201 subcutaneous(SC) injection. |
| Placebo | DRUG | subcutaneous(SC) injection |
Inclusion Criteria: 1. 12≤ age ≤75 years at the screening visit, male or female; 2. Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014\[1\]) at the screening, visit and: a) The subject has been su...
CBP-201 is an investigational small molecule being developed for moderate-to-severe atopic dermatitis and moderate to severe persistent asthma with type 2 inflammation. It has been studied in Phase 2 clinical trials for these conditions.
CBP-201 is being developed by Connect Biopharma Holdings Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CNTB.
CBP-201 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in atopic dermatitis and one in asthma, and is not yet approved by regulatory authorities.
CBP-201 has been studied in three completed Phase 2 trials: NCT04444752 in moderate-to-severe atopic dermatitis, NCT04773678 in moderate to severe persistent asthma, and NCT05017480 in moderate to severe atopic dermatitis in China.
CBP-201 is the sole name provided for this investigational drug. No alternative names have been reported for this compound.
CBP-201 is a small molecule, but its specific molecular target has not been disclosed. It is being studied for its efficacy and safety in inflammatory conditions such as atopic dermatitis and asthma.